JPMorgan Chase & Co. Lowers Holdings in Progyny, Inc. $PGNY

JPMorgan Chase & Co. decreased its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 28.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 888,721 shares of the company’s stock after selling 346,587 shares during the quarter. JPMorgan Chase & Co.’s holdings in Progyny were worth $19,125,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Danske Bank A S purchased a new stake in Progyny in the third quarter worth about $630,000. CANADA LIFE ASSURANCE Co increased its position in Progyny by 2.9% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 77,595 shares of the company’s stock valued at $1,660,000 after purchasing an additional 2,164 shares during the period. Dark Forest Capital Management LP increased its position in Progyny by 104.6% during the 3rd quarter. Dark Forest Capital Management LP now owns 30,739 shares of the company’s stock valued at $662,000 after purchasing an additional 15,717 shares during the period. PharVision Advisers LLC bought a new stake in shares of Progyny in the 3rd quarter valued at about $448,000. Finally, Quarry LP raised its holdings in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

NASDAQ:PGNY opened at $17.75 on Thursday. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The stock has a market capitalization of $1.45 billion, a P/E ratio of 27.31, a P/E/G ratio of 1.04 and a beta of 1.01. The company’s 50-day simple moving average is $20.88 and its 200-day simple moving average is $22.44.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PGNY. Truist Financial dropped their price objective on shares of Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, March 2nd. Barclays reduced their price objective on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a research note on Friday, March 20th. Canaccord Genuity Group dropped their target price on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.91.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 7,455 shares of company stock valued at $129,515 in the last three months. 9.40% of the stock is owned by company insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.